Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 05, 2026
DataAggregated Company Financials
Companies548
  • 7D0.6%
  • 3M7.5%
  • 1Y35.2%
  • YTD11.2%

Over the last 7 days, the Biotech industry has remained flat, although notably Regeneron Pharmaceuticals gained 9.4%. As for the the longer term, the industry is up 35% over the past 12 months. Looking forward, earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 05 Aug 2026US$1.4tUS$171.8b-US$12,525,853,989.5817.3x-111.1x8.1x
Fri, 03 Jul 2026US$1.4tUS$169.9b-US$12,055,337,781.6917.3x-118.1x8.4x
Sun, 31 May 2026US$1.3tUS$170.1b-US$12,181,974,969.1216.2x-107.2x7.7x
Tue, 28 Apr 2026US$1.3tUS$166.0b-US$11,971,624,927.8917.3x-107.7x7.8x
Thu, 26 Mar 2026US$1.2tUS$166.1b-US$14,897,815,988.9015.7x-83.1x7.4x
Sat, 21 Feb 2026US$1.3tUS$168.0b-US$13,498,381,572.3922.1x-99.6x8x
Mon, 19 Jan 2026US$1.2tUS$163.5b-US$15,150,311,707.6019.7x-80.8x7.5x
Wed, 17 Dec 2025US$1.2tUS$163.7b-US$15,629,818,633.6018.6x-78.1x7.5x
Fri, 14 Nov 2025US$1.2tUS$163.8b-US$16,256,883,029.7417.8x-73.3x7.3x
Sun, 12 Oct 2025US$1.1tUS$163.4b-US$18,215,104,196.5216.6x-62.2x6.9x
Tue, 09 Sep 2025US$1.1tUS$163.6b-US$18,335,721,970.2215.3x-59.5x6.7x
Thu, 07 Aug 2025US$1.0tUS$161.7b-US$14,985,569,307.7316.9x-67.1x6.2x
Sat, 05 Jul 2025US$960.2bUS$155.8b-US$23,415,675,000.5617.3x-41x6.2x
Mon, 02 Jun 2025US$908.2bUS$155.9b-US$23,672,769,787.0415.6x-38.4x5.8x
Wed, 30 Apr 2025US$795.9bUS$119.3b-US$30,922,989,483.0020.4x-25.7x6.7x
Fri, 28 Mar 2025US$816.7bUS$118.6b-US$37,006,972,359.4322.1x-22.1x6.9x
Sun, 23 Feb 2025US$863.3bUS$117.3b-US$37,606,528,073.3717x-23x7.4x
Tue, 21 Jan 2025US$947.4bUS$149.4b-US$26,290,369,541.3617.3x-36x6.3x
Thu, 19 Dec 2024US$1.0tUS$149.9b-US$26,462,738,539.2415.4x-37.8x6.7x
Sat, 16 Nov 2024US$1.0tUS$150.0b-US$26,800,374,726.0816x-38.7x6.9x
Mon, 14 Oct 2024US$902.0bUS$113.1b-US$36,040,263,614.5420.6x-25x8x
Wed, 11 Sep 2024US$894.1bUS$113.1b-US$35,660,564,622.3222.3x-25.1x7.9x
Fri, 09 Aug 2024US$1.2tUS$166.7b-US$32,150,549,450.8023.9x-36.2x7x
Sun, 07 Jul 2024US$1.1tUS$164.5b-US$28,073,537,735.6427.9x-40.3x6.9x
Tue, 04 Jun 2024US$1.1tUS$164.6b-US$26,680,256,870.3727.7x-42.1x6.8x
Thu, 02 May 2024US$1.1tUS$165.0b-US$26,426,226,136.7823.2x-41x6.6x
Sat, 30 Mar 2024US$1.2tUS$164.4b-US$23,362,713,195.1520.8x-50.5x7.2x
Mon, 26 Feb 2024US$1.2tUS$166.6b-US$21,694,939,476.2110.8x-54.3x7.1x
Wed, 24 Jan 2024US$1.4tUS$204.7b-US$22,529,001,992.0018.1x-63.5x7x
Fri, 22 Dec 2023US$1.3tUS$204.8b-US$22,148,191,573.0019x-60x6.5x
Sun, 19 Nov 2023US$1.2tUS$204.7b-US$22,079,556,420.0018.1x-54.7x5.9x
Tue, 17 Oct 2023US$1.3tUS$207.4b-US$13,067,799,538.0017.3x-97.1x6.1x
Thu, 14 Sep 2023US$1.3tUS$207.5b-US$12,611,945,630.0017.6x-101.4x6.2x
Sat, 12 Aug 2023US$1.3tUS$207.7b-US$12,540,100,481.0017.1x-102.7x6.2x
Price to Earnings Ratio

-102.7x


Total Market Cap: US$1.3tTotal Earnings: -US$12,540,100,481.00Total Revenue: US$207.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -60.4x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.1x.
Past Earnings Growth
  • Losses for companies in the Biotechs industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have declined 6.1% per year.
  • This means that the cost of doing business could be reducing since sales have declined but losses haven't fallen much further.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market4.85%
Healthcare-1.96%
Biotech0.62%
Biotech0.62%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
REGN Regeneron PharmaceuticalsUS$760.669.4%
+US$5.2b		37.0%PE17.5x
GILD Gilead SciencesUS$135.251.9%
+US$3.1b		22.6%PE18.2x
NTRA NateraUS$275.198.4%
+US$3.1b		99.2%PS15.8x
RVMD Revolution MedicinesUS$193.466.9%
+US$2.7b		427.6%PB27.4x
ROIV Roivant SciencesUS$34.595.2%
+US$1.2b		196.9%PS3012.1x

Latest News

TWST
US$99.45
Twist Bioscience
7D
16.4%
1Y
284.0%
Seeking Alpha • 2h

Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety

Summary Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve. While the outlook is positive, Twist's valuation is now demanding, increasing risk and limiting near-term upside. Read the full article on Seeking Alpha
NTRA
US$275.19
Natera
7D
8.4%
1Y
99.2%
ABBV
US$243.80
AbbVie
7D
-7.4%
1Y
22.8%
SYRE
US$104.94
Spyre Therapeutics
7D
7.2%
1Y
557.5%
VRTX
US$478.71
Vertex Pharmaceuticals
7D
-1.0%
1Y
24.1%
AMGN
US$390.02
Amgen
7D
-0.8%
1Y
30.0%
KRYS
US$324.77
Krystal Biotech
7D
-10.8%
1Y
136.5%
REGN
US$760.66
Regeneron Pharmaceuticals
7D
9.4%
1Y
37.0%
ROIV
US$34.59
Roivant Sciences
7D
5.2%
1Y
196.9%
Narrative Update • Aug 03

ROIV: Late Stage Data Catalysts Will Drive Future Upside Potential

Roivant Sciences' updated analyst price target has shifted to $42, with analysts citing refreshed models after recent earnings, pipeline updates, and IMVT-1402 trial data as key drivers behind the change from the prior $45 view. Analyst Commentary Recent Street research on Roivant Sciences has leaned constructive, with several bullish analysts revising their models after earnings, pipeline updates, and new IMVT-1402 data.
NBIX
US$166.06
Neurocrine Biosciences
7D
-8.1%
1Y
29.3%
ALNY
US$219.00
Alnylam Pharmaceuticals
7D
-23.6%
1Y
-48.8%
SMMT
US$13.76
Summit Therapeutics
7D
7.5%
1Y
-51.8%
Seeking Alpha • Jul 31

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

Summary Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically significant PFS but only a favorable trend in OS; updated data with a hazard ratio of 0.76 has been submitted. Competition is intensifying, with multiple large pharmas developing similar VEGF/PD-1 bispecifics; no acquisition or major partnership offers have materialized for SMMT. I remain cautious, awaiting further data readouts and clarity on SMMT’s ability to compete in the $90bn PD-1 therapy market if approval is secured. Read the full article on Seeking Alpha
INCY
US$120.60
Incyte
7D
-7.2%
1Y
55.2%
Analysis Article • Jul 31

Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

A week ago, Incyte Corporation ( NASDAQ:INCY ) came out with a strong set of quarterly numbers that could potentially...
RVMD
US$193.46
Revolution Medicines
7D
6.9%
1Y
427.6%
GILD
US$135.25
Gilead Sciences
7D
1.9%
1Y
22.6%
Narrative Update • Jul 28

GILD: Future Returns Will Depend On HIV Franchise And Oncology Execution

Analysts have nudged their price targets for Gilead Sciences lower by a few dollars, generally citing updated models that factor in company commentary on Q2 R&D, a softer outlook for HIV PrEP expansion, and ongoing competitive pressure in oncology and cell therapy, alongside mixed views on the long acting HIV pipeline. Analyst Commentary Recent research on Gilead Sciences points to a more cautious tone around the stock, even as views remain mixed.
INSM
US$98.75
Insmed
7D
-5.2%
1Y
-11.5%